Current Treatment Options in Neurology

, Volume 12, Issue 2, pp 100–112 | Cite as

Treatment Options in the Management of Status Epilepticus

Critical Care Neurology

Opinion statement

Status epilepticus treatment involves the use of several pharmacologic compounds, which are conceptually divided into three successive and additional lines of action. Because of their rapid onset of action, benzodiazepines represent the first approach; these are followed by classic antiepileptic drugs that are administered intravenously. In refractory episodes, pharmacologic coma induction with an appropriate anesthetic is advocated. Apart from first-line compounds, the level of evidence for medications used in status epilepticus is extremely limited. It is important to specifically address etiology in order to maximize the impact of the antiepileptic therapy. Fine-tuning of the treatment strategy, mainly regarding the choice of whether to induce coma, should be approached by balancing the benefits of rapid control of the status epilepticus with the risks of adverse effects. Although each status epilepticus episode should be treated as rapidly as possible, it appears advisable to reserve coma induction for those forms, such as generalized convulsive status, that have been shown to present a consistent risk of neurologic sequelae.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. 1.
    Chen JW, Wasterlain CG: Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006, 5(3):246–256.CrossRefPubMedGoogle Scholar
  2. 2.
    Lowenstein DH, Alldredge BK: Status epilepticus. N Engl J Med 1998, 338(14):970–976.CrossRefPubMedGoogle Scholar
  3. 3.
    Lowenstein DH, Bleck T, Macdonald RL: It’s time to revise the definition of status epilepticus. Epilepsia 1999, 40(1):120–122.CrossRefPubMedGoogle Scholar
  4. 4.
    Mazarati AM, Wasterlain CG: N-methyl-D-aspartate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 1999, 265(3):187–190.CrossRefPubMedGoogle Scholar
  5. 5.
    Holtkamp M, Othman J, Buchheim K, Meierkord H: Diagnosis of psychogenic nonepileptic status epilepticus in the emergency setting. Neurology 2006, 66(11):1727–1729.CrossRefPubMedGoogle Scholar
  6. 6.
    Leppik IE, Derivan AT, Homan RW, et al.: Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983, 249(11):1452–1454.CrossRefPubMedGoogle Scholar
  7. 7.
    Alldredge BK, Gelb AM, Isaacs SM, et al.: A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001, 345(9):631–637.CrossRefPubMedGoogle Scholar
  8. 8.
    Treiman DM, Meyers PD, Walton NY, et al.: A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998, 339(12):792–798.CrossRefPubMedGoogle Scholar
  9. 9.
    Treiman DM, Walton NY, Collins JF, VA Status Epilepticus Cooperative Study Group: Treatment of status epilepticus if first drug fails [abstract J.02]. Epilepsia 1999, 40(Suppl 7):243.Google Scholar
  10. 10.
    Treiman DM: Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia 1989, 30(Suppl 2):S4–S10.CrossRefPubMedGoogle Scholar
  11. 11.
    Browne TR: The pharmacokinetics of agents used to treat status epilepticus. Neurology 1990, 40(5 Suppl 2):28–32.PubMedGoogle Scholar
  12. 12.
    Crevoisier C, Delisle MC, Joseph I, Foletti G: Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Eur Neurol 2003, 49(3):173–177.CrossRefPubMedGoogle Scholar
  13. 13.
    McIntyre J, Robertson S, Norris E, et al.: Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005, 366(9481):205–210.CrossRefPubMedGoogle Scholar
  14. 14.
    Misra UK, Kalita J, Patel R: Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006, 67(2):340–342.CrossRefPubMedGoogle Scholar
  15. 15.
    Sheth RD, Gidal BE: Intravenous valproic acid for myoclonic status epilepticus. Neurology 2000, 54(5):1201.PubMedGoogle Scholar
  16. 16.
    Agarwal P, Kumar N, Chandra R, et al.: Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007, 16(6):527–532.CrossRefPubMedGoogle Scholar
  17. 17.
    Gilad R, Izkovitz N, Dabby R, et al.: Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 2008, 118(5):296–300.CrossRefPubMedGoogle Scholar
  18. 18.
    Rossetti AO, Bromfield EB: Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav 2006, 8(3):651–654.CrossRefPubMedGoogle Scholar
  19. 19.
    • Ruegg S, Naegelin Y, Hardmeier M, et al.: Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 2008, 12(3):477–480.CrossRefPubMedGoogle Scholar
  20. 20.
    • Knake S, Gruener J, Hattemer K, et al.: Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008, 79(5):588–589.CrossRefPubMedGoogle Scholar
  21. 21.
    • Kellinghaus C, Berning S, Besselmann M: Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009, 14(2):429–431.CrossRefPubMedGoogle Scholar
  22. 22.
    Walton NY, Uthman BM, El Yafi K, et al.: Phenytoin penetration into brain after administration of phenytoin or fosphenytoin. Epilepsia 1999, 40(2):153–156.CrossRefPubMedGoogle Scholar
  23. 23.
    Yu KT, Mills S, Thompson N, Cunanan C: Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 2003, 44(5):724–726.CrossRefPubMedGoogle Scholar
  24. 24.
    Perucca E: Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16(10):695–714.CrossRefPubMedGoogle Scholar
  25. 25.
    Sinha S, Naritoku DK: Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000, 55(5):722–724.PubMedGoogle Scholar
  26. 26.
    Edwards KR, Glantz MJ: The pharmacokinetics of levetiracetam in human cerebrospinal fluid and serum: a controlled dose-ranging study in malignant brain-tumor patients. Epilepsia 2004, 45(Suppl 7):121.Google Scholar
  27. 27.
    Fountain NB, Lothman EW: Pathophysiology of status epilepticus. J Clin Neurophysiol 1995, 12(4):326–342.PubMedGoogle Scholar
  28. 28.
    •• Holtkamp M: The anaesthetic and intensive care of status epilepticus. Curr Opin Neurol 2007, 20(2):188–193.CrossRefPubMedGoogle Scholar
  29. 29.
    Claassen J, Hirsch LJ, Emerson RG, Mayer SA: Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002, 43(2):146–153.CrossRefPubMedGoogle Scholar
  30. 30.
    Rossetti AO, Logroscino G, Bromfield EB: Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005, 62(11):1698–1702.CrossRefPubMedGoogle Scholar
  31. 31.
    Bayliff CD, Schwartz ML, Hardy BG: Pharmacokinetics of high-dose pentobarbital in severe head trauma. Clin Pharmacol Ther 1985, 38(4):457–461.PubMedGoogle Scholar
  32. 32.
    Wessen A, Persson PM, Nilsson A, Hartvig P: Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. J Clin Anesth 1994, 6(3):193–198.CrossRefPubMedGoogle Scholar
  33. 33.
    Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003, 29(9):1417–1425.CrossRefPubMedGoogle Scholar
  34. 34.
    • Zarovnaya EL, Jobst BC, Harris BT: Propofol-associated fatal myocardial failure and rhabdomyolysis in an adult with status epilepticus. Epilepsia 2007, 48(5):1002–1006.CrossRefPubMedGoogle Scholar
  35. 35.
    Rossetti AO, Reichhart MD, Schaller MD, et al.: Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004, 45(7):757–763.CrossRefPubMedGoogle Scholar
  36. 36.
    Naritoku DK, Sinha S: Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology 2000, 54(6):1366–1368.PubMedGoogle Scholar
  37. 37.
    Claassen J, Hirsch LJ, Emerson RG, et al.: Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001, 57(6):1036–1042.PubMedGoogle Scholar
  38. 38.
    • Rossetti AO, Logroscino G, Milligan TA, et al.: Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008, 255(10):1561–1566.CrossRefPubMedGoogle Scholar
  39. 39.
    • Drislane FW, Blum AS, Lopez MR, et al.: Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours. Epilepsia 2009, 50(6):1566–1571.CrossRefPubMedGoogle Scholar
  40. 40.
    Holtkamp M, Othman J, Buchheim K, et al.: A “malignant” variant of status epilepticus. Arch Neurol 2005, 62(9):1428–1431.CrossRefPubMedGoogle Scholar
  41. 41.
    • Pruss H, Holtkamp M: Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008, 82(2–3):219–222.CrossRefPubMedGoogle Scholar
  42. 42.
    Mirsattari SM, Sharpe MD, Young GB: Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol 2004, 61(8):1254–1259.CrossRefPubMedGoogle Scholar
  43. 43.
    Towne AR, Garnett LK, Waterhouse EJ, et al.: The use of topiramate in refractory status epilepticus. Neurology 2003, 60(2):332–334.PubMedGoogle Scholar
  44. 44.
    Iannetti P, Spalice A, Parisi P: Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005, 46(6):967–969.CrossRefPubMedGoogle Scholar
  45. 45.
    Bodenant M, Moreau C, Sejourne C, et al.: [Interest of the ketogenic diet in a refractory status epilepticus in adults]. Rev Neurol (Paris) 2008, 164(2):194–199.Google Scholar
  46. 46.
    Robakis TK, Hirsch LJ: Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care 2006, 4(1):35–46.CrossRefPubMedGoogle Scholar
  47. 47.
    De Herdt V, Waterschoot L, Vonck K, et al.: Vagus nerve stimulation for refractory status epilepticus. Eur J Paediatr Neurol 2009, 13(3):286–289.CrossRefPubMedGoogle Scholar
  48. 48.
    • Corry JJ, Dhar R, Murphy T, Diringer MN: Hypothermia for refractory status epilepticus. Neurocrit Care 2008, 9(2):189–197.CrossRefPubMedGoogle Scholar
  49. 49.
    Lhatoo SD, Alexopoulos AV: The surgical treatment of status epilepticus. Epilepsia 2007, 48(Suppl 8):61–65.CrossRefPubMedGoogle Scholar
  50. 50.
    Jordan KG, Hirsch LJ: In nonconvulsive status epilepticus (NCSE), treat to burst-suppression: pro and con. Epilepsia 2006, 47(Suppl 1):41–45.CrossRefPubMedGoogle Scholar
  51. 51.
    Kaplan PW: No, some types of nonconvulsive status epilepticus cause little permanent neurologic sequelae (or: “the cure may be worse than the disease”). Neurophysiol Clin 2000, 30(6):377–382.CrossRefPubMedGoogle Scholar
  52. 52.
    Cereda C, Berger MM, Rossetti AO: Bowel ischemia: a rare complication of thiopental treatment for status epilepticus. Neurocrit Care 2009, 10(3):355–358.CrossRefPubMedGoogle Scholar
  53. 53.
    • Rossetti AO, Oddo M, Liaudet L, Kaplan PW: Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology 2009, 72(8):744–749.CrossRefPubMedGoogle Scholar
  54. 54.
    Dara SI, Tungpalan LA, Manno EM, et al.: Prolonged coma from refractory status epilepticus. Neurocrit Care 2006, 4(2):140–142.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Service de NeurologieLausanneSwitzerland

Personalised recommendations